Ariad @ASH released ponatinib updates just now ~Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent ~Pooled Phase 1 and PACE analysis of CP-CML patients with T315I shows 83 percent estimated to maintain major cytogenetic response at four years http://www.nasdaq.com/press-release/ariad-announces-data-presentations-at-american-society-of-hematology-meeting-20161206-00292#ixzz4S3qJBxDH